
ACT Brief: Zip Code Trial Access, Smaller Biotech APAC Perceptions, and Pimjetmi Tumor Approval
13.11.2026
0:00
1:30
In today’s ACT Brief, we examine how ZIP code shapes trial availability and enrollment, why smaller biotechs hold outdated views of APAC sites, and how FDA approved Pimjetmi for symptomatic tenosynovial giant cell tumor.
Więcej odcinków z kanału "Applied Clinical Trials"



Nie przegap odcinka z kanału “Applied Clinical Trials”! Subskrybuj bezpłatnie w aplikacji GetPodcast.








